Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Gourzoulidis GeorgeOresteia ZisimopoulouAndrianos LiavasCharalampos TzanetakosPublished in: Expert review of pharmacoeconomics & outcomes research (2023)
generation TKIs for previously untreated patients with ALK+ aNCSLC in Greece.